The effect of hypertension and left ventricular hypertrophy on the lower range of coronary autoregulation. Harrison DG, Florentine MS, Brooks LA, Cooper SM, Marcus ML (1988) Circulation 77: 1108-15 The effect of cardiac hypertrophy on the coronary collateral circulation. Harrison DG, Barnes DH, Hiratzka LF, Eastham CL, Kerber RE, Marcus ML (1985) Circulation 71: 1135-45 A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension. Lewis J, Greene T, Appel L, Contreras G, Douglas J, Lash J, Toto R, Van Lente F, Wang X, Wright JT, AASK Study Group (2004) J Am Soc Nephrol 15: 3175-83 Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type 1 receptor in vivo. Nakamura S, Nakamura I, Ma L, Vaughan DE, Fogo AB (2000) Kidney Int 58: 251-9 Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC (2002) Kidney Int 62: 929-39 Uric acid and the state of the intrarenal renin-angiotensin system in humans. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, Hollenberg NK, Fisher ND (2004) Kidney Int 66: 1465-70 Hypertension and proteinuria: long-term sequelae of uninephrectomy in humans. Hakim RM, Goldszer RC, Brenner BM (1984) Kidney Int 25: 930-6 Effect of heparin on the glomerular structure and function of remnant nephrons. Ichikawa I, Yoshida Y, Fogo A, Purkerson ML, Klahr S (1988) Kidney Int 34: 638-44 CXCL16: a chemokine-causing chronic kidney disease. Norlander AE, Saleh MA, Madhur MS (2013) Hypertension 62: 1008-10 Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M, Rostand S, Hiremath L, Sika M, Kendrick C, Hu B, Greene T, Appel L, Phillips RA, African American Study of Kidney Disease and Hypertension Collaborative Research Group (2009) Hypertension 53: 20-7 Relationship between body mass index and proteinuria in hypertensive nephrosclerosis: results from the African American Study of Kidney Disease and Hypertension (AASK) cohort. Toto RD, Greene T, Hebert LA, Hiremath L, Lea JP, Lewis JB, Pogue V, Sika M, Wang X, AASK Collaborative Research Group (2010) Am J Kidney Dis 56: 896-906 Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Lewis JB, Berl T, Bain RP, Rohde RD, Lewis EJ (1999) Am J Kidney Dis 34: 809-17 A 19-year-old man with hypertension, proteinuria, and renal insufficiency. Broumand V, Paueksakon P, Lewis JB, Nadeau J, Fogo A (1999) Am J Kidney Dis 34: 768-74 Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy. Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH (2011) Clin J Am Soc Nephrol 6: 1025-31 Renovascular hypertension: anatomic and renal function changes during drug therapy. Dean RH, Kieffer RW, Smith BM, Oates JA, Nadeau JH, Hollifield JW, DuPont WD (1981) Arch Surg 116: 1408-15 Cardiovascular effects of microinjection of angiotensin II in the brainstem of renal hypertensive rats. Mosqueda-Garcia R, Tseng CJ, Appalsamy M, Robertson D (1990) J Pharmacol Exp Ther 255: 374-81 Superoxide dismutase and oxidative stress in Dahl salt-sensitive and -resistant rats. Meng S, Roberts LJ, Cason GW, Curry TS, Manning RD (2002) Am J Physiol Regul Integr Comp Physiol 283: R732-8 Mechanisms of progression of chronic kidney disease. Fogo AB (2007) Pediatr Nephrol 22: 2011-22 An unusual etiology of hypertension in a 5-year-old boy. Menschik D, Lovvorn H, Hill A, Kelly P, Jones DP (2002) Pediatr Nephrol 17: 524-6
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.